MedPath

The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors

Phase 3
Completed
Conditions
Vitamin D Deficiency
Interventions
Registration Number
NCT02750293
Lead Sponsor
University of Tromso
Brief Summary

Six-hundred subjects with vitamin D deficiency will be randomized to vitamin D 3000 IU per day versus placebo for 4 months, with effects on cardiovascular risk factors as main endpoint

Detailed Description

Vitamin D is a hormone with effects not only on the skeleton, but on most tissues in the body. Lack of vitamin D is associated with cardio-vascular disease (CVD) and type 2 diabetes, and also with risk factors for these diseases like hypertension, dyslipidemia, insulin resistance, and endothelial dysfunction. However, intervention studies with vitamin D have been inconclusive regarding diseases and risk factors. Most of these studies were done in white, Western populations in subjects fairly vitamin D sufficient, and accordingly, no benefits were to be expected. Also, in many studies the doses of vitamin D have been too low, and the studies underpowered. To firmly establish the role of vitamin D regarding CVD risk factors we will in the present study include 600 subjects with vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) \< 30 nmol/L) and randomize to high dose vitamin D (3000 IU per day) versus placebo for four months. The subjects will be recruited based on 25(OH)D measurements in the forthcoming 7th survey in the Tromsø study where more than 20 000 subjects are expected to attend. If our hypotheses are correct and the vitamin D supplement has a positive effect, this will be of great importance not only in countries with low sun exposure, but particularly for subjects in developing countries where vitamin D deficiency is highly prevalent.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
411
Inclusion Criteria
  • participated in The 7th survey in The Tromsø study
  • vitamin D deficiency
Exclusion Criteria
  • primary hyperparathyroidism
  • granulomatous disease
  • reduced kidney function
  • systolic blood pressure > 174 mmHg
  • diastolic blood pressure > 104 mmHg
  • diabetes
  • renal stones last 5 years
  • use of solarium on regular basis
  • planned holidays in tropical areas
  • clinical depression
  • clinical signs of vitamin D deficiency (muscle weakness)
  • use of vitamin D supplements
  • serious illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placeboPlaceboplacebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
cholecalciferolCholecalciferolvitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
Primary Outcome Measures
NameTimeMethod
Change from baseline in systolic and diastolic blood pressure4 months
Secondary Outcome Measures
NameTimeMethod
Change from baseline in score on Becks Depression Inventory4 months
Change from baseline in cognitive function evaluated with The Twelve Word Memory Test4 months
Change from baseline in cognitive function evaluated with The Digit Symbol Coding Test4 months
Change from baseline in cognitive function evaluated with The Tapping Test4 months
Change from baseline in arterial stiffness and endothelial function evaluated with pulse wave velocity4 months
Change from baseline in arterial stiffness and endothelial function evaluated with augmentation index (AIX)4 months
Change from baseline in arterial stiffness and endothelial function evaluated with the subendocardial viability ratio (SEVR)4 months
Change from baseline in hand-grip, quadriceps and biceps muscle strength measured by hand held dynamometry .4 months
Change from baseline in number of subjects with nasal staphylococcus aureus colonization4 months
Change from baseline in bone mass density measured with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip4 months
Change from baseline in the bone turnover marker serum type 1 procollagen (P1NP)4 months
Change from baseline in the bone turnover marker serum collagen type 1 cross-linked C-telopeptide (CTX-1)4 months
Change from baseline in serum marker of interferon-γ mediated macrophage activation4 months
Change from baseline in serum vitamin B6 status.4 months
Change from baseline in the glycosylation marker HbA1c4 months
Change from baseline in the glycosylation marker the receptor for advanced glycosylation end products (s-RAGE)4 months
Change from baseline in the glycosylation marker carboxy-methyllysine4 months
Change from baseline in psoriasis Activity in subjects with psoriasis evaluated with the Self-Administered Psoriasis Area Severity Index (SAPASI)4 months
Change from baseline in number of subjects with nocturnal legg cramps4 months
Change from baseline in sleep pattern evaluated with the Tromsø Study 7th Survey sleep pattern questionnaire4 months
Change from baseline in the serum total cholesterol4 months
Change from baseline in the serum HDL-cholesterol4 months
Change from baseline in the serum LDL-cholesterol4 months
Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Dermatological Life Quality Index (DLQI)4 months
Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Psoriasis Area Severity Index (PASI)4 months
Change from baseline in transcriptomic profile (mRNA) in adipose tissue biopsies4 months
Change from baseline in the serum triglycerides4 months
Change from baseline in the serum Apolipoprotein A14 months
Change from baseline in the serum Apolipoprotein B,4 months
Change from baseline in insulin resistance evaluated with the homeostasis model assessment (HOMA) index based on fasting serum glucose and serum insulin4 months
Change from baseline in proteomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)4 months
Change from baseline in metabolomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)4 months

Trial Locations

Locations (1)

University Hospital of North Norway

🇳🇴

Tromsø, Norway

© Copyright 2025. All Rights Reserved by MedPath